C. Wanner

Most-cited papers

1. Empagliflozin in Patients with Chronic Kidney Disease

   W. Herrington, N. Staplin, C. Wanner, J. B. Green +35 more

   2022New England Journal of Medicine1,521 citations Open access

   Semantic Scholar

   Save

2. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).

   Giuseppe Mancia Chairperson, Reinhold Kreutz Co-Chair, M. Brunström, M. Burnier +55 more

   2023Journal of Hypertension1,327 citations Open access

   Semantic Scholar

   Save

3. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

   P. Rossing, M. L. Caramori, Juliana C. N. Chan, H. Heerspink +13 more

   2022Kidney International1,211 citations Open access

   Semantic Scholar

   Save

4. Impact of Diabetes on The Effects Of Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials

   C. Baigent, J. Emberson, R. Haynes, W. Herrington +34 more

   2022The Lancet576 citations Open access

   Semantic Scholar

   Save

5. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association

   Carmine Zoccali, F. Mallamaci, M. Adamczak, R. D. de Oliveira +10 more

   2023Cardiovascular Research334 citations Open access

   Semantic Scholar

   Save

6. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.

   P. Rossing, M. L. Caramori, Juliana C. N. Chan, H. Heerspink +18 more

   2022Kidney International237 citations Open access

   Semantic Scholar

   Save

7. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

   M. Blazing, E. Braunwald, J. A. de Lemos, S. Murphy +106 more

   2022The Lancet218 citations Open access

   Semantic Scholar

   Save

8. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

   S. Navaneethan, S. Zoungas, M. L. Caramori, Juliana C. N. Chan +18 more

   2023Annals of Internal Medicine198 citations Open access

   Semantic Scholar

   Save

9. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

   B. Neuen, M. Oshima, R. Agarwal, C. Arnott +16 more

   2022Circulation190 citations Open access

   Semantic Scholar

   Save

10. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study

    H. Reinecke, C. Engelbertz, R. Bauersachs, G. Breithardt +13 more

    2022Circulation150 citations Open access

    Semantic Scholar

    Save

11. What should European nephrology do with the new CKD-EPI equation?

    R. Gansevoort, H. Anders, M. Cozzolino, D. Fliser +4 more

    2022Nephrology, Dialysis and Transplantation93 citations Open access

    Semantic Scholar

    Save

12. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease

    Dan-Qin Sun, G. Targher, C. Byrne, D. Wheeler +44 more

    2023Hepatobiliary surgery and nutrition91 citations Open access

    Semantic Scholar

    Save

13. Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study

    Edouard L. Fu, M. Evans, J. Carrero, H. Putter +9 more

    2021British medical journal73 citations Open access

    Semantic Scholar

    Save

14. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.

    M. Böhm, J. Butler, G. Filippatos, J. Ferreira +11 more

    2022Journal of the American College of Cardiology66 citations Open access

    Semantic Scholar

    Save

15. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes

    M. Davies, H. Drexel, F. Jornayvaz, Z. Pataky +2 more

    2022Cardiovascular Diabetology64 citations Open access

    Semantic Scholar

    Save

16. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

    William G. Christoph Jennifer B. Sibylle J. Parminder Kait Herrington Wanner Green Hauske Judge Mayne Ng Samm, W. Herrington, C. Wanner, J. Green +38 more

    2022Nephrology, Dialysis and Transplantation62 citations Open access

    Semantic Scholar

    Save

17. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients

    Ashutosh Kumar Singh, B. Čižman, K. Carroll, J. McMurray +19 more

    2022JAMA Internal Medicine59 citations Open access

    Semantic Scholar

    Save

18. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR‐Preserved trial

    Abhinav Sharma, J. Ferreira, F. Zannad, S. Pocock +8 more

    2023European Journal of Heart Failure58 citations Open access

    Semantic Scholar

    Save

19. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

    Priyadarshini Balasubramanian, C. Wanner, J. Ferreira, A. Ofstad +3 more

    2022Journal of Clinical Endocrinology and Metabolism49 citations Open access

    Semantic Scholar

    Save

20. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria

    J. McGill, H. Haller, P. Roy-Chaudhury, A. Cherrington +4 more

    2022BMJ Open Diabetes Research & Care48 citations Open access

    Semantic Scholar

    Save

21. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association

    A. Ortiz, C. Wanner, R. Gansevoort

    2022Clinical Kidney Journal47 citations Open access

    Semantic Scholar

    Save

22. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes

    P. Sarafidis, R. Agarwal, B. Pitt, C. Wanner +14 more

    2023American Society of Nephrology. Clinical Journal45 citations Open access

    Semantic Scholar

    Save

23. An expert consensus on the recommendations for the use of biomarkers in Fabry disease.

    A. Burlina, E. Brand, D. Hughes, I. Kantola +5 more

    2023Molecular Genetics and Metabolism42 citations Open access

    Semantic Scholar

    Save

24. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

    Katherine R. Tuttle, A. Levin, M. Nangaku, T. Kadowaki +7 more

    2022Diabetes Care42 citations Open access

    Semantic Scholar

    Save

25. Symptom Burden before and after Dialysis Initiation in Older Patients

    E. D. de Rooij, Y. Meuleman, J. de Fijter, K. Jager +10 more

    2022American Society of Nephrology. Clinical Journal41 citations Open access

    Semantic Scholar

    Save

26. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

    M. Böhm, S. Anker, F. Mahfoud, L. Lauder +10 more

    2022European Heart Journal38 citations Open access

    Semantic Scholar

    Save

27. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

    P. Sarafidis, F. Iatridi, C. Ferro, M. Alexandrou +8 more

    2023Clinical Kidney Journal37 citations Open access

    Semantic Scholar

    Save

28. Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.

    J. Butler, M. Packer, T. Siddiqi, M. Böhm +11 more

    2023Journal of the American College of Cardiology37 citations Open access

    Semantic Scholar

    Save

29. Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community.

    C. Wanner, A. Ortiz, W. Wilcox, R. Hopkin +13 more

    2023Molecular Genetics and Metabolism36 citations Open access

    Semantic Scholar

    Save

30. Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced

    F. Zannad, J. Ferreira, J. Gregson, B. J. Kraus +8 more

    2022European Journal of Heart Failure36 citations

    Semantic Scholar

    Save

31. Association between CKD-MBD and mortality in older patients with advanced CKD—results from the EQUAL study

    Lorenza Magagnoli, M. Cozzolino, F. Caskey, M. Evans +12 more

    2023Nephrology, Dialysis and Transplantation35 citations Open access

    Semantic Scholar

    Save

32. Quality of Life before and after the Start of Dialysis in Older Patients

    E. D. de Rooij, Y. Meuleman, J. de Fijter, S. le Cessie +12 more

    2022American Society of Nephrology. Clinical Journal34 citations Open access

    Semantic Scholar

    Save

33. The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study

    L. Dai, Z. Massy, P. Stenvinkel, N. Chesnaye +13 more

    2022American Journal of Clinical Nutrition34 citations Open access

    Semantic Scholar

    Save

34. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients

    D. Coyne, Ashutosh Kumar Singh, R. Lopes, C. Bailey +10 more

    2022American Society of Nephrology. Clinical Journal34 citations Open access

    Semantic Scholar

    Save

35. Assessing Global Kidney Nutrition Care

    A. Wang, I. Okpechi, F. Ye, C. Kovesdy +27 more

    2022American Society of Nephrology. Clinical Journal32 citations Open access

    Semantic Scholar

    Save

36. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes

    S. Kahl, A. Ofstad, B. Zinman, C. Wanner +4 more

    2022Diabetes, obesity and metabolism31 citations Open access

    Semantic Scholar

    Save

37. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone

    R. Agarwal, B. Pitt, P. Rossing, S. Anker +11 more

    2023JAMA cardiology30 citations Open access

    Semantic Scholar

    Save

38. Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients

    E. Levtchenko, A. Servais, S. Hulton, G. Ariceta +10 more

    2022Clinical Kidney Journal29 citations Open access

    Semantic Scholar

    Save

39. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association.

    A. Ortiz, C. Wanner, R. Gansevoort

    2022European Journal of Preventive Cardiology28 citations Open access

    Semantic Scholar

    Save

40. Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease

    Wisanne M Bakker, H. Heerspink, S. Berger, Christoph Wanner +119 more

    2025Nephrology, Dialysis and Transplantation27 citations Open access

    Semantic Scholar

    Save

41. Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR‐Preserved trial

    M. Böhm, J. Butler, M. Krawczyk, F. Mahfoud +11 more

    2023European Journal of Heart Failure26 citations Open access

    Semantic Scholar

    Save

42. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association

    A. Ortiz, C. Wanner, R. Gansevoort

    2022Nephrology, Dialysis and Transplantation26 citations Open access

    Semantic Scholar

    Save

43. Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice.

    N. Desai, S. Navaneethan, S. Nicholas, K. Pantalone +4 more

    2023Journal of diabetes and its complications25 citations Open access

    Semantic Scholar

    Save

44. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD

    H. Heerspink, L. Inker, H. Tighiouart, Willem H. Collier +20 more

    2023Journal of the American Society of Nephrology25 citations Open access

    Semantic Scholar

    Save

45. Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients

    Z. Massy, T. Merkling, S. Wagner, N. Girerd +5 more

    2022American Society of Nephrology. Clinical Journal25 citations Open access

    Semantic Scholar

    Save

46. X‐chromosomal inactivation patterns in women with Fabry disease

    Laura Wagenhäuser, V. Rickert, C. Sommer, C. Wanner +3 more

    2022Molecular Genetics & Genomic Medicine25 citations Open access

    Semantic Scholar

    Save

47. Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study.

    Jonas Müntze, K. Lau, M. Cybulla, E. Brand +6 more

    2022Molecular Genetics and Metabolism24 citations Open access

    Semantic Scholar

    Save

48. Association of Longitudinal High-Sensitivity Troponin T With Mortality in Patients With Chronic Kidney Disease.

    N. Chesnaye, Ehab Al-sodany, K. Szummer, P. Bárány +8 more

    2022Journal of the American College of Cardiology22 citations Open access

    Semantic Scholar

    Save

49. Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up.

    E. D. de Rooij, J. de Fijter, S. le Cessie, E. Hoorn +11 more

    2023American Journal of Kidney Diseases21 citations Open access

    Semantic Scholar

    Save

50. Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial

    M. Böhm, J. Butler, F. Mahfoud, G. Filippatos +10 more

    2022European Journal of Heart Failure19 citations Open access

    Semantic Scholar

    Save